GeneDx (NASDAQ:WGS) versus Joint (NASDAQ:JYNT) Critical Comparison
by Mitch Edgeman · The Markets DailyJoint (NASDAQ:JYNT – Get Free Report) and GeneDx (NASDAQ:WGS – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.
Profitability
This table compares Joint and GeneDx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Joint | 6.49% | 12.02% | 3.47% |
| GeneDx | -23.41% | 4.12% | 2.26% |
Risk and Volatility
Joint has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Joint and GeneDx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Joint | 1 | 2 | 0 | 0 | 1.67 |
| GeneDx | 1 | 0 | 7 | 1 | 2.89 |
GeneDx has a consensus target price of $89.57, suggesting a potential downside of 11.40%. Given GeneDx’s stronger consensus rating and higher probable upside, analysts clearly believe GeneDx is more favorable than Joint.
Institutional and Insider Ownership
76.9% of Joint shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 30.2% of Joint shares are held by company insiders. Comparatively, 25.2% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Joint and GeneDx”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Joint | $54.90 million | 2.17 | $2.91 million | $0.27 | 31.26 |
| GeneDx | $427.54 million | 7.05 | -$21.02 million | ($3.64) | -27.77 |
Joint has higher earnings, but lower revenue than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.
Summary
Joint beats GeneDx on 8 of the 15 factors compared between the two stocks.
About Joint
The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.